24Business
Akeso announces the completion of the patient’s enrollment in the clinical examination of the Phase III (Harmoni-6), comparing the Ivonescimacb and Tilellizumab to treat the SQ-NSCLC first line
Akeso announces the completion of the patient’s enrollment in the clinical examination of the Phase III (Harmoni-6), comparing the Ivonescimacb and Tilellizumab to treat the SQ-NSCLC first line
Source link
